Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Timothy Chiang is an analyst at Capital One. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/28/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 03/15/2024 | ANIP | Buy Now | ANI Pharmaceuticals | $67.71 | — | Timothy Chiang24% | — | Initiates | → Overweight | Get Alert |
| 11/03/2022 | AKYA | Buy Now | Akoya Biosciences | $1.49 | 1175.17% | Timothy Chiang24% | → $19 | Initiates | → Overweight | Get Alert |
| 02/11/2022 | PTGX | Buy Now | Protagonist Therapeutics | $49.71 | 10.64% | Timothy Chiang24% | → $55 | Initiates | → Buy | Get Alert |
| 10/05/2020 | AMPH | Buy Now | Amphastar Pharma | $28.37 | — | Timothy Chiang24% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 09/01/2020 | IDYA | Buy Now | IDEAYA Biosciences | $17.42 | 60.73% | Timothy Chiang24% | → $28 | Initiates | → Outperform | Get Alert |
| 10/26/2018 | SGYP | Buy Now | Synergy Pharmaceuticals | — | — | Timothy Chiang24% | — | Downgrade | Buy → Neutral | Get Alert |
| 10/04/2017 | MYL | Buy Now | Mylan | — | — | Timothy Chiang24% | $42 → $45 | Maintains | Buy | Get Alert |
| 07/21/2017 | PTGX | Buy Now | Protagonist Therapeutics | $49.71 | -27.58% | Timothy Chiang24% | → $36 | Initiates | → Buy | Get Alert |
| 08/25/2015 | SGYP | Buy Now | Synergy Pharmaceuticals | — | — | Timothy Chiang24% | → $11 | Initiates | → Buy | Get Alert |
| 06/18/2015 | MYL | Buy Now | Mylan | — | — | Timothy Chiang24% | → $85 | Initiates | → Buy | Get Alert |
